Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii

Mohammad Hamidian, Steven J. Nigro

Microbial Genomics · 2019 · Review

doi:10.1099/mgen.0.000306

Abstract

Acinetobacter baumannii is a nosocomial pathogen that has emerged as a global threat because of high levels of resistance to many antibiotics, particularly those considered to be last-resort antibiotics, such as carbapenems. Although alterations in the efflux pump and outer membrane proteins can cause carbapenem resistance, the main mechanism is the acquisition of carbapenem-hydrolyzing oxacillinase-encoding genes. Of these, oxa23 is by far the most widespread in most countries, while oxa24 and oxa58 appear to be dominant in specific regions. Historically, much of the global spread of carbapenem resistance has been due to the dissemination of two major clones, known as global clones 1 and 2, although new lineages are now common in some parts of the world. The analysis of all publicly available genome sequences performed here indicates that ST2, ST1, ST79 and ST25 account for over 71 % of all genomes sequenced to date, with ST2 by far the most dominant type and oxa23 the most widespread carbapenem resistance determinant globally, regardless of clonal type. Whilst this highlights the global spread of ST1 and ST2, and the dominance of oxa23 in both clones, it could also be a result of preferential selection of carbapenem-resistant strains, which mainly belong to the two major clones. Furthermore, ~70 % of the sequenced strains have been isolated from five countries, namely the USA, PR China, Australia, Thailand and Pakistan, with only a limited number from other countries. These genomes are a vital resource, but it is currently difficult to draw an accurate global picture of this important superbug, highlighting the need for more comprehensive genome sequence data and genomic analysis.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Data Summary

1. Three thousand five hundred and seventy-five A. baumannii genomes were retrieved from the GenBank non-redundant and Whole Genome Shotgun (WGS) databases and analysed here. The full strain list and the ftp addresses used to retrieve the genomes are publicly available at https://www.ncbi.nlm.nih.gov/genome/?term=Acinetobacter+baumannii.

2. Variants of the beta-lactam resistance genes used for analyses were retrieved from the NCBI Antimicrobial Resistance Reference Gene database, which is publicly available at https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/.

Carbapenem antibiotics were once considered to be a last resort, but the rapid worldwide dissemination of multiply antibiotic-resistant (MAR) bacteria has made them the first, or only, treatment option left for many infections. However, organisms that are also resistant to carbapenems are now becoming commonplace. Diverse populations of carbapenem-resistant Acinetobacter baumannii (CRAB) have been observed worldwide, mainly driven by the spread of two MAR clonal lineages. Next-generation sequencing technologies have provided an unprecedented level of information to study the evolution and epidemiology of carbapenem resistance in this priority pathogen. Here, we delve into this rich resource to not only enhance what is known about the mechanisms and epidemiology of carbapenem resistance in A. baumannii, but also understand what is missing. Understanding the factors that lead CRAB to spread so successfully throughout the world is crucial to curtail its spread and prevent it from becoming universally untreatable.

Introduction

Antibiotic resistance has increased to dangerously high levels in bacterial strains recovered in all parts of the world, threatening our ability to treat common infectious diseases. Acinetobacter baumannii is one such organism and a member of the ESKAPE group of six bacterial pathogens ( E nterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species) that are major causes of antibiotic-resistant infections. A. baumannii is a Gram-negative opportunistic nosocomial pathogen that is most notably responsible for pneumonia, along with infections of burns and other wounds. It can survive harsh environmental pressures, such as desiccation and pH extremes, making management of these infections particularly challenging in the intensive care and burns units of hospitals.

A. baumannii has been recognized as a threat since the 1970s due to the rapid development of resistance to a wide range of antibiotics, including last-resort treatments such as carbapenems. Often, there are very limited or no remaining options to treat A. baumannii infections. In 2017, this prompted the World Health Organization (WHO) to recognize carbapenem-resistant A. baumannii (CRAB) as the critical, number 1 priority among a published list of 12 antibiotic-resistant bacteria that pose the greatest threat to modern medicine, underlining the clinical significance and global burden of infections caused by CRAB.

Here, we discuss the emergence, molecular mechanisms and global spread of CRAB. To develop a snapshot of the geographical distribution of genomes sequenced so far and their carbapenem resistance gene (CRG) repertoire, we explore over 3500 A. baumannii genomes deposited in the GenBank non-redundant and Whole Genome Shotgun (WGS) databases. We also examine the genomic context of CRGs in all 128 complete genomes to further understand the role of mobile genetic elements in the spread of CRGs in A. baumannii.

Global spread of carbapenem-resistant Acinetobacter baumannii

Carbapenem antibiotics such as meropenem and imipenem belong to the ß-lactam family and remain active against most ß-lactamase-producing organisms, including those with extended spectrum ß-lactamase enzymes. Carbapenems are considered to be a front-line treatment for infections caused by multiply resistant bacteria, but carbapenem resistance is increasingly common in A. baumannii, imposing huge financial and healthcare burdens.

The number of studies in PubMed reporting CRAB increased from a single report in 2000 to over 266 in 2018, highlighting its global dissemination. This has been largely due to inter- and intra-hospital transfer of resistant strains over the last two decades. One classic example involving both intra-hospital and international transfer was the dramatic increase in A. baumannii infections in soldiers injured in war zones in Iraq and Afghanistan between 2006–2008. These infections often were resistant to multiple antibiotics and one study showed that 37 % of isolates recovered from injured deployed military personnel were also resistant to carbapenems. A subsequent study found that isolates recovered from injured soldiers were genetically related to those recovered on field hospital surfaces rather than pre-injury colonization or introduction at the time of injury. It has been suggested that the return of soldiers from combat zones was an important factor that contributed to the epidemiology of A. baumannii infections in the USA.

Outbreaks caused by CRAB have been reported from civilian hospitals in the USA, Canada, South America, Europe, Africa, the Middle East, Southeast Asia, Australia and many more countries. Generally, these CRAB outbreaks have been caused by the spread of a few specific clones that were already resistant to a wide range of antibiotics. Although it was initially thought that these clones were limited to Europe, they have now been reported in different countries of all inhabited continents, raising widespread clinical concerns. The two major clones responsible for most of these outbreaks are now commonly referred to as global clone 1 (GC1) and global clone 2 (GC2), but have also been referred to as international clones 1 and 2.

As of early April 2019, there were 3609 A. baumannii genomes available in the GenBank non-redundant and WGS databases (https://www.ncbi.nlm.nih.gov/genome/?term=Acinetobacter+baumannii). Here, these genomes were downloaded, and MLST types were determined in silico using MLST v2.16.1 (https://github.com/tseemann/mlst) followed by screening for antibiotic resistance genes using Abricate v0.8.10 (https://github.com/tseemann/abricate). These data were combined with the metadata available for each genome using R v3.5.2. Thirty-four duplicate, or passaged, isolates were removed from the analysis. Of the 3575 remaining genomes analysed here, 2364 (66 %) were members of GC1 (173 genomes) and GC2 (2191 genomes). These clones are defined here as ST1, representing GC1s according to the Institut Pasteur MLST scheme, and ST2, representing GC2s, along with their single-locus variants (ST1, SLV1, ST2 and SLV2 in Fig. 1a). However, ST2 itself is by far the dominant type, with 2105 genomes (59 %) among the available complete and draft genomes (Fig. 1a). This is also consistent with a large number of previous publications that continue to report outbreaks due to these two global clones, with GC2s accounting for the bulk of CRAB outbreaks. The global distribution of CRAB has been heavily influenced by the spread of GC2 isolates, with 1678 GC2 isolates also carrying at least 1 CRG. Only 109 of the 3575 genomes were GC1 isolates that harboured at least 1 CRG. Two other lineages contributed almost as much as GC1, with 91 and 53 belonging to ST79 and ST25, respectively.

Molecular mechanisms of carbapenem resistance in A. baumannii

Many carbapenem resistance mechanisms have been described in A. baumannii, including alterations or loss of outer membrane proteins such as CarO and modifications of the AdeABC resistance nodulation division (RND) efflux pump. Although efflux modifications contribute to carbapenem resistance in A. baumannii, on their own they are are not sufficient to cause clinically relevant resistance. Carbapenem resistance in A. baumannii is largely due to the horizontal acquisition of genes that encode carbapenem-hydrolyzing enzymes belonging to either Ambler class D (oxacillinases) or class B (metallo-ß-lactamases).

Oxacillinases

Oxacillinase enzymes (OXAs) are a heterogeneous family and, to date, several groups of carbapenem-hydrolyzing oxacillinases have been described in A. baumannii, most notably OXA-23, OXA-24, OXA-58, OXA-143, OXA-235 and an intrinsic OXA, designated OXA-Ab for simplicity. Genes encoding these acquired carbapenem-hydrolyzing enzymes are the main cause of carbapenem resistance in A. baumannii. Generally, oxacillinases only hydrolyze carbapenems weakly and are often poorly expressed, hence they cannot cause clinically relevant levels of resistance on their own. However, their expression is often enhanced by the insertion of an upstream IS, which enhances expression by providing a strong promoter, causing high resistance levels. Reports of the prevalence of these genes vary by geographical distribution, but oxa23 is the most frequently described.

The intrinsic oxaAb

The oxaAb gene (also known as bla OXA51-like) occurs naturally in A. baumannii and is used as a marker for speciation. So far, over 180 oxaAb variants (https://www.lahey.org/studies/) have been identified in A. baumannii strains. The most common variants are oxa69 and oxa66, which are associated with members of GC1 and GC2, respectively. It has been suggested that strains with an ISAba1 upstream of oxaAb can be carbapenem-resistant, but more than just overexpression of oxaAb is needed for significant levels of carbapenem resistance. However, further work is required to understand the contribution of oxaAb overexpression in different genetic backgrounds and whether specific amino acid alterations in OXA-Ab also play a significant role.

Acquired oxacillinases

The oxa23 gene was first characterized in an A. baumannii strain recovered in Scotland in 1985, shortly after the introduction of carbapenems as therapeutic agents. Later, it was shown to have originated from the chromosome of Acinetobacter radioresistens, where it was mobilized into A. baumannii by ISAba1. To date, more than 25 variants of oxa23 have been identified (https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/BETA-LACTAM).

The oxa58 gene was first identified on a plasmid from a multiply antibiotic-resistant A. baumannii recovered in France in 2003, and to date six further variants have been found. The oxa58 gene has been associated with hospital outbreaks in Europe, the USA, South America, Australia and Africa.

The oxa24 gene was originally identified in the chromosome of a CRAB isolate recovered in Spain. However, now CRAB strains carrying the oxa24 gene, and its variants, often on small plasmids, have been recovered in hospital outbreaks worldwide. This oxacillinase group consists of eight close relatives and amongst them OXA-25, OXA-26, OXA-40/OXA-24 (a sequencing error initially misclassified these as different) and OXA-72 are the most prevalent variants.

Other class D carbapenemases, such as those belonging to the OXA-143 and OXA-235 families, have also been associated with CRAB outbreaks in several countries, although they are reported less frequently and are generally considered to be minor causes for carbapenem resistance in A. baumannii.

Other carbapenemases

Other CRGs, such as those encoding metallo-ß-lactamases (MBL), bla VIM, bla IMP and bla NDM, or class A carbapenemases, bla KPC and bla GES-11, are also seen in A. baumannii. However, unlike Enterobacteriaceae, they are not common in A. baumannii. The bla NDM gene is often located in a mobile 10 kb ISAba125-bounded composite transposon called Tn125, which is commonly seen on conjugative plasmids.

Genome sequencing; opportunities and challenges

In recent years, whole-genome sequencing (WGS) technologies and advances in bioinformatic tools have revolutionized the study of bacterial pathogens, enabling gene screening and phylogenomic studies of outbreak strains with unprecedented resolution. The first A. baumannii genome was sequenced in 2006, ATCC 17978, followed by an epidemic GC1 strain in France, a non-clonal strain from human body lice and a carbapenem-resistant GC2 strain recovered in Italy. A few additional strains, including three CRAB GC1 strains (AB0057, AB056 and AB059) recovered from military patients at Walter Reed Army Medical Center, were also sequenced in the USA between 2008–2010. However, as short-read sequencing technologies became more affordable and accessible, the number of genomes sequenced exponentially increased from 2014 onwards, and by early April 2019, over 3500 A. baumannii genomes were available (Fig. 1c).

Amongst the 3575 non-redundant genome sequences studied here, 2345 (66 %) contained at least one CRG and of these, 1918 genomes (82 %) carry at least 1 copy of oxa23 (Fig. 1b), consistent with worldwide reports that oxa23 is overwhelmingly predominant in A. baumannii. However, these sequences have a skewed geographical distribution, with 69 % (2481/3575) of all sequenced strains isolated from only five countries, namely the USA, PR China, Thailand, Australia and now Pakistan (Fig. 2). Notably, a total of 57 % (838/1466), 89 % (387/436), 84 % (224/266), 70 % (159/226) and 93 % (81/87) of genomes sequenced from the USA, PR China, Thailand, Australia and Pakistan, respectively, carry a CRG of one kind (Fig. 1b). However, it is unclear to what extent these CRG proportions reflect true population trends in these countries or whether they are a result of preferential selection of CRAB isolates for large-scale WGS projects, highlighting the need to sequence all A. baumannii that cause infection, regardless of their resistance phenotype. Hence, it is difficult to draw a clear picture of the true global A. baumannii population, including CRAB, unless more representative strains from Europe, the Middle East, Russia and Africa are sequenced and made publicly available.

Furthermore, whilst GC1 and GC2 are the most common clones in many countries, this may not always be true. For instance, GC1 and GC2 strains do not seem to be the dominant types in South American countries (n=10/70), Tunisia (n=1/13), Tanzania (n=5/14), Poland (n=0/10) and Japan (n=7/26) (Fig. 2), although more genomes are needed to confirm this. Although GC2 appears to be the dominant type in some countries, for example Spain, the genomes show that oxa24 and oxa58 are the dominant CRGs rather than oxa23 (Fig. 2). However, given the relative paucity of genome data from these countries, caution needs to be exercised when drawing such conclusions.

Studying the genetic environment of antibiotic resistance genes, including CRGs, often provides valuable information on the origin, emergence, evolution and spread of resistance throughout bacterial populations. Most of the currently available A. baumannii genomes have been sequenced using short-read technologies such as Illumina HiSeq or MiSeq. Although the data produced by these methods are sufficient to identify antibiotic resistance genes or draw phylogenetic trees, they lack the power to resolve complex resistance regions, which are often made up of numerous repeated elements. These regions tend to compromise assembly and can only be resolved manually via PCR and Sanger sequencing or by using long-read sequencing technologies such as Oxford Nanopore Technology (ONT) or Pacific Biosciences (PacBio). Indeed, only 128 (4 %) genomes have been fully assembled and the majority of these were sequenced with PacBio (data not shown).

Genomic contexts and the role of mobile genetic elements in the spread of carbapenem resistance genes

The oxa23 gene has moved into chromosomes and plasmids, on multiple occasions, via the transposons Tn2006, Tn2007, Tn2008, Tn2008B, Tn2009 and AbaR4 (Fig. 3a). The oxa23-containing Tn2006 is the most commonly found transposon, and hence the most important in CRAB. It is a 4.8 kb class I transposon that consists of a central 2445 bp segment bounded by two inversely oriented copies of ISAba1 and generates a 9 bp target site duplication (TSD) upon insertion, characteristic of ISAba1 transposition. Tn2006 can move independently and is found in many different chromosomal and plasmid contexts in distantly related A. baumannii strains. In members of a distinct clade within GC1 lineage 1, Tn2006 has been found in a specific chromosomal location. Tn2006 within AbaR4 is also located in the chromosomal comM gene in a member of another GC1 lineage, lineage 2, where the A. baumannii Resistance Island (AbaR) is often present. In GC2 isolates, oxa23 is often found in Tn2006 alone or in derivatives of AbaR4 as components of A. baumannii Genomic Resistance Island (AbGRI), which resides in the same location in comM as AbaR does in GC1s. Tn2008, Tn2008B and Tn2009 (Fig. 3 and Table S1, available in the online version of this article) are also seen in several chromosomal positions and are not associated with genomic islands.

Plasmids also play a crucial role in the spread of multiple carbapenem resistance genes in A. baumannii. For instance, large conjugative plasmids (80–130 kbp) encoding the RepAci6 replication initiation protein are implicated in the spread of oxa23 in GC1 and GC2, as well as strains that do not belong to these clones. To date, several oxa23 transposons have been found in different locations of related RepAci6 plasmids. Moreover, oxa23 in Tn2006 was recently found in a RepAci1 plasmid where it was shown to be mobilized by a RepAci6 plasmid, further emphasizing the role of plasmids encoding RepAci6 in spreading and now in the mobilization of carbapenem resistance between disparate strains.

Currently, there are 128 completed A. baumannii genomes in GenBank, of which 91 carry at least one CRG. Examining these 91 genomes shows that 9 of the 11 oxa23-containing GC1s (Table S1) carry oxa23, either in Tn2006 in the chromosome or, in one case, Tn2006 in AbaR4 in comM. In several strains, AbaR4 is found in a RepAci6 plasmid (Table S1). Members of GC2 often carry Tn2006 in the chromosome as part of AbGRI variants, with several strains carrying two oxa23 copies in this island (Table S1). Four strains, two from the Republic of Korea and two from Pakistan (Table S1), carried Tn2008B (Fig. 3a) in different chromosomal positions flanked by different TSDs. This suggests that Tn2008B is still quite active, as it was chromosomally incorporated on multiple occasions. Other GC2s carry either Tn2006 or Tn2008 in variants of RepAci6 plasmids (Table S1). Tn2009 appears most commonly in GC2 isolates from PR China (n=17) and the Republic of Korea (n=19), some with multiple chromosomal copies in tandem (Table S1). In non-GC1 or GC2 strains, chromosomal Tn2006 appears most often. Interestingly, 39 complete genomes harbour more than 1 copy of oxa23. Most often, there are multiple copies in the chromosome, although some also have oxa23 on a plasmid. This raises the question of whether these isolates, or those that harbour multiple families of CRG, have a selective advantage compared to those with fewer copies of oxa23, and warrants further investigation.

New oxa23-containing structures are still being identified, such as an ISAba1- and ISAba33-flanked transposon (Fig. 3c) described in 2016. Indeed, during the course of this work we found oxa23 in yet another novel structure with the features of a composite transposon, in the chromosome of a Canadian strain (BA30 in Fig. 3c). This 3902 bp transposon contains oxa23 flanked by directly oriented copies of ISAba1. Two copies of this transposon were found at different chromosomal locations (bases 3303155–3307056 and 4295797–4299698 in CP009257), with each copy flanked by novel 9 bp TSDs, providing evidence that it moves independently. Hence, we named this transposon Tn6549 (Fig. 3c). Tn6549 appears to be a derivative of Tn2008, rather than Tn2008B, as there is 27 bp between the start of the oxa23 gene and the ISAba1 sequence, which is indicative of Tn2008. The central segment of Tn6549 contains oxa23 and an open reading frame of unknown function (orf in Fig. 3c). A sequence identical to this open reading frame was found in the chromosome of Acinetobacter sp. strain ACNIH1 (GenBank accession no. CP026420) and fragments of this open reading frame are in several Acinetobacter lwoffii and Acinetobacter haemolyticus plasmids (e.g. GenBank accession nos CP038010 and CP032112).

The oxa58 gene is often embedded in the ISAba3::ISAba2-oxa58-ISAba3 structure, and carried on non-conjugative plasmids encoding both RepAci1 and RepAci10. This entire structure is now known to be surrounded by short inversely oriented inverted repeats similar to chromosomal dif sites, now referred to as pdif, targeted by XerC–XerD site-specific recombinases. This dif module containing oxa58 is found in different plasmid backgrounds, indicating that it is a discrete mobile element that is responsible for the movement of oxa58, rather than the ISs that surround it. Analysis of the completed genomes also indicated that oxa58 is mainly associated with dif modules often carried by similar small plasmids encoding RepAci1 and RepAci10 (Table S1).

The oxa24 gene is commonly seen in 8–12 kb plasmids that encode RepAci1 or RepAci2, as part of discrete dif modules flanked by pdif sites. This was also the case in all complete genomes with oxa24, (Table S1), adding further evidence that small plasmids, particularly those encoding RepAci1 and RepAci2, are a major force behind the global spread of oxa58 and oxa24.

The oxa253 gene, a variant of oxa143, may also occur in pdif modules, as it has been found near a single pdif site in a context similar to oxa24 in a RepAci2 plasmid. The oxa235 gene, and its variants oxa236 and oxa237, are often found in single-nucleotide variants of a 5.2 kb ISAba1-bounded composite transposon called Tn6252, which has been found in chromosomes and plasmids.

Conclusions

Antibiotic resistance is on the rise and we are already running out of antibiotics to treat CRAB, which are unfortunately most commonly resistant to a wide range of additional antibiotics. Members of GC1 and GC2 are responsible for the bulk of globally disseminated multi-resistant A. baumannii, including CRAB. Although the current publicly available genomes provide an invaluable snapshot of the evolution and spread of CRAB throughout much of the world, the paucity of publicly available genome sequence data from regions such as Europe, the Middle East, Russia, Africa and South America has made it difficult to draw an accurate global picture of the spread of A. baumannii clones, CRGs and their phylogeny. Notably, whilst oxa23 is predominant globally, this is not always the case, particularly in countries such as Spain, Germany or Tunisia (Fig. 1b), further emphasizing the need for more sequencing coverage to understand why these different CRGs dominate in different regions. Sequencing strains from diverse regions is vital in understanding the evolutionary trajectory of the two major global clones, as well as other emerging clones, such as ST79 or ST25.

Expanding the use of long-read sequencing will facilitate a better understanding of the mobile elements responsible for moving CRGs and their broader contexts, while also enabling the characterization of further novel transposons and conjugative and mobilizable plasmids. It is now clear that alternative methods of horizontal gene transfer, such as dif modules and homologous recombination, play a larger role in the dissemination of CRGs than previously thought. Completing genome and plasmid assemblies will provide further knowledge regarding how widespread and important these mechanisms truly are. Indeed, this understanding will be vital in curtailing the future spread of CRGs in A. baumannii, as the issues of CRG spread via successful strains or clones and the spread of CRGs to susceptible strains via HGT are distinct problems that require different solutions. This will be crucial to identify molecular and epidemiological diagnostic markers to help identify resistant clones and track their spread. A more geographically uniform distribution of genome sequence data is also needed to further monitor plasmid movement and identify the true proportion of A. baumannii harbouring conjugative plasmids carrying bla NDM and other CRGs that are common in other species. With the lack of new antibiotics to treat CRAB, and the uncertainty about whether new drugs would even be effective, infection control policy and practice built upon the framework of these phylogenetic and epidemiological analyses are vital in stopping the spread of CRAB. Without such interventions, we will enter an era where common infections and minor injuries caused by CRAB can once again kill.

Data bibliography

1. GenBank non-redundant and Whole Genome Shotgun (WGS) databases. Complete ftp addresses used to retrieved the genomes are publicly available at https://www.ncbi.nlm.nih.gov/genome/?term=Acinetobacter+baumannii.

2. National Centre for Biotechnology Information (NCBI) Antimicrobial Resistance Reference Gene database, publicly available at https://www.ncbi.nlm.nih.gov/pathogens/isolates#/refgene/.

References 163

  1. 1.

    Watkins RR, Bonomo RA. Overview: global and local impact of antibiotic resistance. Infect Dis Clin North Am. 2016;30:313-322.

    Not in our library10.1016/j.idc.2016.02.001

  2. 2.

    Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079-1081.

    Not in our library10.1086/533452

  3. 3.

    Towner KJ. Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4-5 November 1996 at Eilat, Israel. J Med Microbiol. 1997;46:721-746.

    Not in our library10.1099/00222615-46-9-721

  4. 4.

    Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-165.

    Not in our library10.1128/cmr.9.2.148

  5. 5.

    Antunes LCS, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71:292-301.

    Not in our library10.1111/2049-632x.12125

  6. 6.

    Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity. IUBMB Life. 2011;63:1055-1060.

    Not in our library10.1002/iub.533

  7. 7.

    Devaud M, Kayser FH, Bächi B. Transposon-mediated multiple antibiotic resistance in Acinetobacter strains. Antimicrob Agents Chemother. 1982;22:323-329.

    Not in our library10.1128/aac.22.2.323

  8. 8.
  9. 9.

    Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol. 2008;190:8053-8064.

    Not in our library10.1128/jb.00834-08

  10. 10.

    Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36:85-98.

    Not in our library10.1055/s-0034-1398388

  11. 11.

    Nigro SJ, Hall RM. Tn6167, an antibiotic resistance island in an Australian carbapenem-resistant Acinetobacter baumannii GC2, ST92 isolate. J Antimicrob Chemother. 2012;67:1342-1346.

    Not in our library10.1093/jac/dks037

  12. 12.

    Visca P, Seifert H, Towner KJ. Acinetobacter infection--an emerging threat to human health. IUBMB Life. 2011;63:1048-1054.

    Not in our library10.1002/iub.534

  13. 13.

    WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organisation. 2017.

    Not in our library

  14. 14.

    Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969-976.

    Not in our library10.1128/aac.01009-09

  15. 15.
  16. 16.

    Adams MD, Chan ER, Molyneaux ND, Bonomo RA. Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:3569-3577.

    Not in our library10.1128/aac.00057-10

  17. 17.

    Perez F, Ponce-Terashima R, Adams MD, Bonomo RA. Are we closing in on an "elusive enemy"? The current status of our battle with Acinetobacter baumannii. Virulence. 2011;2:86-90.

    Not in our library10.4161/viru.2.2.15748

  18. 18.

    Hamidian M, Hawkey J, Wick R, Holt KE, Hall RM. Evolution of a clade of Acinetobacter baumannii global clone 1, lineage 1 via acquisition of carbapenem- and aminoglycoside-resistance genes and dispersion of ISAba1. Microb Genom. 2019;5:0.000242.

    Not in our library10.1099/mgen.0.000242

  19. 19.

    Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2001;45:583-588.

    Not in our library10.1128/aac.45.2.583-588.2001

  20. 20.

    Peleg AY, Paterson DL. Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern Med J. 2006;36:479-482.

    Not in our library10.1111/j.1445-5994.2006.01130.x

  21. 21.

    Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-582.

    Not in our library10.1128/cmr.00058-07

  22. 22.

    Zarrilli R, Crispino M, Bagattini M, Barretta E, Di Popolo A, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol. 2004;42:946-953.

    Not in our library10.1128/jcm.42.3.946-953.2004

  23. 23.

    van den Broek PJ, Arends J, Bernards AT, De Brauwer E, Mascini EM, et al. Epidemiology of multiple Acinetobacter outbreaks in the Netherlands during the period 1999-2001. Clin Microbiol Infect. 2006;12:837-843.

    Not in our library10.1111/j.1469-0691.2006.01510.x

  24. 24.

    Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004;53:1063-1066.

    Not in our library

  25. 25.

    Calhoun JH, Murray CK, Manring MM. Multidrug-Resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res. 2008;466:1356-1362.

    Not in our library10.1007/s11999-008-0212-9

  26. 26.

    Griffith ME, Lazarus DR, Mann PB, Boger JA, Hospenthal DR, et al. Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol. 2007;28:720-722.

    Not in our library10.1086/518966

  27. 27.

    Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the walter reed army medical center. Antimicrob Agents Chemother. 2006;50:4114-4123.

    Not in our library10.1128/aac.00778-06

  28. 28.

    Scott P, Deye G, Srinivasan A, Murray C, Moran K, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007;44:1577-1584.

    Not in our library10.1086/518170

  29. 29.
  30. 30.

    Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother. 2006;50:2941-2945.

    Not in our library10.1128/aac.00116-06

  31. 31.

    Dy ME, Nord JA, LaBombardi VJ, Kislak JW. The emergence of resistant strains of Acinetobacter baumannii: clinical and infection control implications. Infect Control Hosp Epidemiol. 1999;20:565-567.

    Not in our library10.1086/501673

  32. 32.

    Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994;344:1329-1332.

    Not in our library10.1016/s0140-6736(94)90694-7

  33. 33.

    Boyd DA, Mataseje LF, Pelude L, Mitchell R, Bryce E, et al. Results from the Canadian nosocomial infection surveillance program for detection of carbapenemase-producing Acinetobacter spp. in Canadian hospitals, 2010-16. J Antimicrob Chemother. 2019;74:315-320.

    Not in our library10.1093/jac/dky416

  34. 34.

    Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, et al. Dissemination of Acinetobacter baumannii clones with OXA-23 carbapenemase in Colombian hospitals. Antimicrob Agents Chemother. 2007;51:2001-2004.

    Not in our library10.1128/aac.00226-07

  35. 35.

    da Silva KE, Maciel WG, Croda J, Cayô R, Ramos AC, et al. A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit. PLoS One. 2018;13:e0209367.

    Not in our library10.1371/journal.pone.0209367

  36. 36.

    Tavares LCB, de Vasconcellos FM, de Sousa WV, Rocchetti TT, Mondelli AL, et al. Emergence and persistence of high-risk clones among MDR and XDR A. baumannii at a Brazilian Teaching Hospital. Front Microbiol. 2018;9:2898.

    Not in our library10.3389/fmicb.2018.02898

  37. 37.

    Merkier AK, Catalano M, Ramírez MS, Quiroga C, Orman B, et al. Polyclonal spread of bla OXA-23 and bla OXA-58 in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries. 2008;2:235-240.

    Not in our library10.3855/jidc.269

  38. 38.

    Opazo-Capurro A, San Martín I, Quezada-Aguiluz M, Morales-León F, Domínguez-Yévenes M, et al. Evolutionary dynamics of carbapenem-resistant Acinetobacter baumannii circulating in Chilean hospitals. Infect Genet Evol. 2019;73:93-97.

    Not in our library10.1016/j.meegid.2019.04.022

  39. 39.

    Sevillano E, Fernández E, Bustamante Z, Zabalaga S, Rosales I, et al. Emergence and clonal dissemination of carbapenem-hydrolysing OXA-58-producing Acinetobacter baumannii isolates in bolivia. J Med Microbiol. 2012;61:80-84.

    Not in our library10.1099/jmm.0.032722-0

  40. 40.

    Schulte B, Goerke C, Weyrich P, Gröbner S, Bahrs C, et al. Clonal spread of meropenem-resistant Acinetobacter baumannii strains in hospitals in the Mediterranean region and transmission to south-west Germany. J Hosp Infect. 2005;61:356-357.

    Not in our library10.1016/j.jhin.2005.05.009

All 163 references

Cited by papers we hold 10

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.